Stockscreener 앱 받기
87.18
0.18%
-0.16
시간 외 거래:
87.18
전일 마감가:
$87.34
열려 있는:
$86.54
하루 거래량:
751.66K
Relative Volume:
0.69
시가총액:
$5.45B
수익:
$209.18M
순이익/손실:
$52.04M
주가수익비율:
122.36
EPS:
0.7125
순현금흐름:
$37.10M
1주 성능:
-1.80%
1개월 성능:
+2.99%
6개월 성능:
+71.99%
1년 성능:
+123.65%
1일 변동 폭
$85.19
$88.16
1주일 범위
$85.19
$89.10
52주 변동 폭
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
87.18 | 5.46B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-12 | 개시 | Leerink Partners | Outperform |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - The Coloradoan
Protagonist Therapeutics Earnings Notes - Trefis
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Daytona Beach News-Journal
Aug Selloffs: Why Protagonist Therapeutics Inc stock is recommended by analystsJuly 2025 Pullbacks & Smart Allocation Stock Reports - moha.gov.vn
Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Chart Watch & Growth Focused Stock Reports - DonanımHaber
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trade Summary & Low Risk Investment Opportunities - DonanımHaber
Why Protagonist Therapeutics Inc. stock is favored by top institutionsPortfolio Risk Report & Fast Gain Stock Tips - DonanımHaber
How Protagonist Therapeutics Inc. stock benefits from strong dollar2025 Risk Factors & Real-Time Volume Spike Alerts - DonanımHaber
Is Protagonist Therapeutics Inc. stock a contrarian buyChart Signals & Consistent Income Trade Recommendations - Улправда
Why Protagonist Therapeutics Inc. stock is recommended by analysts2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6%Should You Sell? - MarketBeat
Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq
Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus
How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - Sahm
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Green Bay Press-Gazette
Three Stocks That May Be Undervalued In December 2025 - Sahm
Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 93.53 USD - Investing.com India
Protagonist Therapeutics stock hits all-time high at 93.53 USD By Investing.com - Investing.com Australia
Citizens maintains Protagonist Therapeutics stock rating, citing rusfertide efficacy By Investing.com - Investing.com Canada
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIX Spike: How Protagonist Therapeutics Inc stock benefits from strong dollar2025 Winners & Losers & Fast Entry Momentum Trade Alerts - moha.gov.vn
How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
High Growth Tech Stocks In The US Market With Potential - Yahoo Finance
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Comet
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - Sahm
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - STT Info
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Central New Jersey News
Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):